Sci2Sci Raises €1.2M for Regulated AI Data Integrity

Berlin-based startup sci2sci has successfully closed a €1.2 million pre-seed funding round, aiming to fortify artificial intelligence applications within highly regulated sectors. The investment, co-led by Heliad and IBB Ventures, with crucial participation from Robin Capital and Superangels, will accelerate the development of the company's novel approach to data verification and traceability.

The core of sci2sci's offering lies in its 'Integrity Cortex' platform, designed to address the critical challenge of fragmented and unverified data prevalent in industries such as biopharmaceuticals. This sector, heavily reliant on meticulous record-keeping for compliance and research integrity, often struggles with data scattered across disparate systems, PDFs, and manual notes. sci2sci's technology creates a connected, auditable network, linking AI-generated insights and enterprise data directly to their verifiable sources.

This focus on verifiable AI is particularly pertinent as the global AI market continues its rapid expansion, projected to reach hundreds of billions of dollars in the coming years. However, the adoption of AI in regulated fields like healthcare and finance is hampered by concerns over data provenance and the potential for AI models to generate inaccurate or misleading information. sci2sci's solution, built upon its open-sourced 'Parseltongue' framework, directly tackles this by embedding verification mechanisms into the AI workflow from the outset, rather than as an afterthought.

The company's 'VectorCat' product further enhances data accessibility by acting as a unified data integration layer. It allows organizations to connect and index information residing in various cloud storage, network drives, and laboratory systems without necessitating costly data migration. This creates a centralized, searchable repository accessible to both human users and AI applications, streamlining operations and research processes.

Founded by Angelina Lesnikova and Valerii Kremnev, sci2sci is already engaging with clients in preclinical research, contract clinical research, and bioprocess operations. The newly secured capital will be instrumental in expanding the engineering team, deepening current client engagements, and broadening its customer base within the biopharma industry. Furthermore, the company intends to adapt its 'Integrity Cortex' solution for other strictly regulated sectors, including the banking industry, where data accuracy and auditability are paramount.

The strategic importance of such solutions is underscored by the increasing regulatory scrutiny on AI deployments. Initiatives like the EU AI Act and similar frameworks globally emphasize the need for transparency and accountability in AI systems. sci2sci's commitment to building trust and security into AI infrastructure positions it to capitalize on this growing demand for compliant and reliable AI solutions in sensitive markets.